Clover Biopharmaceuticals, Ltd. (HKG:2197)
Hong Kong · Delayed Price · Currency is HKD 2.200
-0.030 (-1.35%)
Feb 13, 2026, 4:08 PM HKT
Clover Biopharmaceuticals Revenue
Clover Biopharmaceuticals had revenue of 3.25M CNY in the half year ending June 30, 2025, with 1,166.15% growth. This brings the company's revenue in the last twelve months to 51.77M, up 79.16% year-over-year. In the year 2024, Clover Biopharmaceuticals had annual revenue of 38.42M, down -2.13%.
Revenue (ttm)
51.77M CNY
Revenue Growth
+79.16%
P/S Ratio
51.02
Revenue / Employee
213.06K CNY
Employees
243
Market Cap
2.89B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 38.42M | -836.00K | -2.13% |
| Dec 31, 2023 | 39.26M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Frontage Holdings | 1.99B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.43B |
| AIM Vaccine | 1.38B |
| BioDlink International Company | 1.17B |
| Medtide | 546.29M |
| Mabpharm | 464.53M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| Antengene Corporation | 92.43M |